MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Halozyme Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

61.86 -1.86

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

61.13

Max

63.04

Schlüsselkennzahlen

By Trading Economics

Einkommen

1K

137M

Verkäufe

7.9M

298M

KGV

Branchendurchschnitt

18.604

63.778

EPS

1.26

Gewinnspanne

45.976

Angestellte

350

EBITDA

13M

203M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+7.11% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

690M

7.9B

Vorheriger Eröffnungskurs

63.72

Vorheriger Schlusskurs

61.86

Nachrichtenstimmung

By Acuity

50%

50%

166 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Halozyme Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. März 2025, 19:42 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5. März 2025, 10:30 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1. Nov. 2024, 11:30 UTC

Top News

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Peer-Vergleich

Kursveränderung

Halozyme Therapeutics Inc Prognose

Kursziel

By TipRanks

7.11% Vorteil

12-Monats-Prognose

Durchschnitt 67.5 USD  7.11%

Hoch 78 USD

Tief 53 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Halozyme Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

62.85 / 63.8825Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

166 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.